Download PDF
Thromb Haemost 2003; 89(03): 506-512
DOI: 10.1055/s-0037-1613381
Platelets and Blood Cells
Schattauer GmbH

Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome

Shosaku Nomura
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Shigeru Uehata
2   Otsuka Assay Laboratories, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
,
Sonoko Saito
2   Otsuka Assay Laboratories, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
,
Kazuoki Osumi
2   Otsuka Assay Laboratories, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
,
Yasushi Ozeki
3   Thrombosis and Vascular Research Laboratories, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
,
Yukio Kimura
3   Thrombosis and Vascular Research Laboratories, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
› Author Affiliations
Further Information

Publication History

Received 17 September 2002

Accepted after revision 06 January 2003

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

Platelet-derived microparticles (PDMPs) are produced by platelet activation or physical stimulation under various conditions. To evaluate changes in platelet and chemokine function in patients undergoing percutaneous transluminal coronary angioplasty (PTCA), we measured and compared levels of PDMPs and a C-C chemokine, regulated on activation normally T-cell express and secreted (RANTES), by ELISA. Levels of PDMP and RANTES in patients with acute coronary syndrome were significantly higher than those in the control groups (PDMP: 20.1 ± 2.9 vs 80.4 ± 7.3 U/ml, p < 0.001; RANTES: 18.6 ± 3.7 vs 52.1 ± 4.6 ng/ml, p < 0.01), but did not differ between the control groups and patients with stable angina. PDMP levels were higher in patients with acute myocardial infarction (AMI) than in patients with unstable angina (PDMP:115.0 ± 7.1 vs 63.9 ± 6.2 U/ml, p < 0.001). There was no difference in the RANTES levels, however, between patients with AMI and patients with unstable angina. PDMP and RANTES levels were significantly decreased after PTCA (PDMP, p < 0.001; RANTES, p < 0.05), but without differences between the two groups. In addition, the level of PDMP was significantly correlated with that of RANTES or soluble CD40 ligand. These findings suggest that PTCA may prevent the development of AMI-associated complications in which activated platelets and RANTES play roles. Our ELISA method appears to be sufficient for monitoring PDMP and RANTES levels after PTCA in patients with acute coronary syndrome.

Keywords

Platelet-derived microparticle - acute coronary syndrome - RANTES - ELISA - PTCA
 

  • References

  • 1 Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94: 93-107.
    CrossrefPubMedGoogle Scholar
  • 2 Daae LN, Kierulf P, Landass S, Urdal P. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis. Scand J Clin Lab Invest 1993; 215: 19-27.
    PubMedGoogle Scholar
  • 3 Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
    CrossrefPubMedGoogle Scholar
  • 4 Steele PM, Chesebro JH, Stanson AW, Holmes Jr DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Cir Res 1985; 57: 105-12.
    CrossrefPubMedGoogle Scholar
  • 5 Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. JAMA 1987; 257: 2318-24.
    CrossrefPubMedGoogle Scholar
  • 6 Leatham EW, Bath PM, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73: 10-3.
    PubMedGoogle Scholar
  • 7 Schwager I, Jungi TW. Effect of recombinant cytokines on the induction of macrophage procoagulant activity. Blood 1994; 83: 152-61.
    PubMedGoogle Scholar
  • 8 Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, Kotzsch M, Schomig A. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17: 3399-405.
    CrossrefPubMedGoogle Scholar
  • 9 Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
    PubMedGoogle Scholar
  • 10 Kameyoshi Y, Dorschner A, Mallet I A, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176: 587-92.
    CrossrefPubMedGoogle Scholar
  • 11 Tschoepe D, Schultheiß HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
    CrossrefPubMedGoogle Scholar
  • 12 Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37.
    CrossrefPubMedGoogle Scholar
  • 13 George JN, Thoi LL, McManus LM, Reimann TA. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60: 834-40.
    PubMedGoogle Scholar
  • 14 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express pro-thrombinase activity. J Biol Chem 1988; 263: 18205-12.
    PubMedGoogle Scholar
  • 15 Nomura S, Komiyama Y, Miyake T, Miyazaki Y, Kido H, Suzuki M, Kagawa H, Yanabu M, Takahashi H, Fukuhara S. Amyloid-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994; 72: 519-22.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, Kido H, Kagawa H, Fukuhara S. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995; 116: 235-40.
    CrossrefPubMedGoogle Scholar
  • 17 Dehmer GJ, Nichols TC, Bode AP, Liles D, Sigman J, Li S, Koch G, Tate DA, Griggs TR. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. Am J Cardiol 1997; 80: 871-7.
    CrossrefPubMedGoogle Scholar
  • 18 Nomura S, Suzuki M, Kido H, Yamaguchi K, Fukuroi T, Yanabu M, Soga T, Nagata H, Kokawa T, Yasunaga K. Differences between platelet and microparticle glycoprotein IIb/IIIa. Cytometry 1992; 13: 621-9.
    CrossrefPubMedGoogle Scholar
  • 19 Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404.
    CrossrefPubMedGoogle Scholar
  • 20 Miyamoto S, Marcinkiewicz C, Edmunds Jr LH, Niewiarowski S. Measurement of platelet microparticles during cardiopulmonary bypass by means of capture ELISA for GPIIb/IIIa. Thromb Haemost 1998; 80: 225-30.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y, Ogura H, Nomura S. Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001; 85: 326-30.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
    PubMedGoogle Scholar
  • 23 Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Stieter RM. Macrophage inflammatory protein-1: A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93: 921-8.
    CrossrefPubMedGoogle Scholar
  • 24 Pattison J, Nelson PJ, Huie P, von Leuttichau I, Farshid G, Sibley RK, Krensky AM. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994; 343: 209-11.
    CrossrefPubMedGoogle Scholar
  • 25 Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1, and MIP-1 as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-5.
    CrossrefPubMedGoogle Scholar
  • 26 Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in HIV-1 infection. FASEB J 1998; 12: 79-89.
    CrossrefPubMedGoogle Scholar
  • 27 Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA. Activated platelets signal chemokine synthesiss by human monocytes. J Clin Invest 1996; 97: 1525-34.
    CrossrefPubMedGoogle Scholar
  • 28 Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, Sticherling C, Meinl C, May A, Schomig A. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95: 2387-94.
    CrossrefPubMedGoogle Scholar
  • 29 Nomura S, Imamura A, Okuno M, Kamiyama Y, Fujimura Y, Ikeda Y, Fukuhara S. Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines. Thromb Res 2000; 98: 257-68.
    CrossrefPubMedGoogle Scholar
  • 30 Hsu-Lin S, Berman CL, Furie BC, August D, Furie B. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem 1984; 259: 9121-6.
    PubMedGoogle Scholar
  • 31 Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33: 634-9.
    CrossrefPubMedGoogle Scholar
  • 32 Ikeda H, Nakayama H, Oda T, Kuwano K, Muraishi A, Sugi K, Koga Y, Toshima H. Soluble form of P-selectin in patients with acute myocardial infarction. Coron Artery Dis 1994; 5: 515-8.
    PubMedGoogle Scholar
  • 33 Shimomura H, Ogawa H, Arai H, Moriyama Y, Takazoe K, Hirai N, Kaikita K, Hirashima O, Misumi K, Soejima H, Nishiyama K, Yasue H. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol 1998; 81: 397-400.
    CrossrefPubMedGoogle Scholar
  • 34 Itoh T, Nakai K, Ono M, Hiramori K. Can the risk for acute cardiac events in acute coronary syndrome be indicated by platelet membrane activation marker P-selectin?. Coron Artery Dis 1995; 6: 645-50.
    CrossrefPubMedGoogle Scholar
  • 35 Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelet triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
    CrossrefPubMedGoogle Scholar
  • 36 Viallard JF, Solanilla A, Gauthier B, Contin C, Dechanet J, Grosset C, Moreau JF, Praloran V, Nurden P, Pellegrin JL, Nurden AT, Ripoche I. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99: 2612-4.
    CrossrefPubMedGoogle Scholar
  • 37 Mathur A, Robinson MSC, Cotton J, Martin JF, Erusalimsky JD. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85: 989-94.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.
    CrossrefPubMedGoogle Scholar
  • 39 Kristensen SD, Bath PM, Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990; 24: 19-23.
    CrossrefPubMedGoogle Scholar
  • 40 Stubbs PJ, Laycock J, Alaghband-Zadeh J, Carter G, Noble MIM. Circulating stress hormone and insulin concentrations in acute coronary syndromes: Identification of insulin resistance on admission. Clin Sci 1999; 96: 589-95.
    CrossrefPubMedGoogle Scholar